Henry Schein (HSIC) just deepened its footprint in advanced diagnostics by taking on a new distribution role for Applied BioCode’s MDx-3000 platform and supporting DermaSensor’s expanded rollout of a handheld skin cancer detection device.
These diagnostics partnerships come as Henry Schein’s share price trades at US$88.36, with a 90 day share price return of 8.75% and a year to date share price return of 15.02%. The 1 year total shareholder return of 28.04% suggests that recent momentum has been building rather than fading.
Scan for other healthcare distributors that are pushing into diagnostics momentum and compare Henry Schein’s positioning against a curated list of list of solid balance sheet and fundamentals (23 results)
Henry Schein now trades at US$88.36 while analyst targets and intrinsic value estimates point higher, and the gap is wide. Is the recent diagnostics driven re-rating already generous or still conservative?
Most Popular Narrative: 9.4% Undervalued
The most followed narrative on Henry Schein pegs fair value at $97.56 against the recent $88.36 share price, framing diagnostics and software as central value drivers.
The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion. Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Want to see what kind of revenue mix, profit margins, and future P/E multiple are baked into that $97.56 fair value for Henry Schein? The most followed narrative leans on a detailed set of growth and profitability forecasts, plus a specific discount rate that turns those long range estimates into today’s price anchor. The real question is how those building blocks fit together and which assumptions do the heavy lifting in that valuation story.
Result: Fair Value of $97.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, Henry Schein’s story could change quickly if competitive pricing in key consumables continues to pressure distribution margins or if staffing shortages further limit dental patient volumes.
Find out about the key risks to this Henry Schein narrative.
Next Steps
Mixed views on Henry Schein so far? Act while the data is fresh and form your own stance by weighing the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Henry Schein?
Do not just stop at Henry Schein. Use the Simply Wall Street Screener to spot other opportunities that fit your style before they move without you.
- Target potential value opportunities by scanning a curated universe of companies that currently screen as 31 high quality undervalued stocks.
- Prioritise resilience by zeroing in on businesses that appear in our 11 resilient stocks with low risk scores.
- Hunt for future leaders by focusing on under the radar companies identified as 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com